SCHEDULE 13G Filed 2026-05-27 Event — SEC 0002050709-26-000019 →

Squadron Capital Management LLC → InMed Pharmaceuticals Inc. INM

Stake: — Shares: — Class: Common Shares, no par value

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 6/100

Passive Schedule 13G filer baseline

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

7 transactions

7 buys · 0 sales · 0 awards/exercises

Issuer Cluster

3 13D/G filings on this issuer

2 other filings besides this one

Filer Track Record

3 filings by this filer

2 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 1.00

6,634 shares short · -80.5% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-07-16	Vivo Opportunity, LLC	10%+ owner	Buy	19	$1.55	$29
2026-07-16	Vivo Opportunity, LLC	10%+ owner	Buy	2	$1.55	$3
2026-07-15	Vivo Opportunity, LLC	10%+ owner	Buy	13,761	$1.55	$21K
2026-07-15	Vivo Opportunity, LLC	10%+ owner	Buy	1,389	$1.55	$2K
2026-07-15	ADAR1 Capital Management, LLC	10%+ owner	Buy	1,000	$1.55	$2K
2026-07-14	Vivo Opportunity, LLC	10%+ owner	Buy	4,882	$1.55	$8K
2026-07-14	Vivo Opportunity, LLC	10%+ owner	Buy	493	$1.55	$764

Other 13D/G Filings on InMed Pharmaceuticals Inc.

Filed	Form	Filer	Stake	Shares
2026-06-10	SCHEDULE 13D	Vivo Opportunity Fund Holdings, L.P.	21.70%	718,444	view →
2026-06-05	SCHEDULE 13G	ADAR1 Capital Management, LLC	—	—	view →

Other Filings by Squadron Capital Management LLC

Filed	Form	Issuer	Stake	Shares
2026-10-23	SCHEDULE 13G	TCGX Acquisition Corp. II	—	—	view →
2026-05-19	SCHEDULE 13G	C4 Therapeutics, Inc. CCCC	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →